Another Reason to Spice it Up!
Curcumin, a component of the spice turmeric (Curcuma longa), prevented type 2 diabetes, according to a randomized, placebo-controlled trial recently published in Diabetes Care.(1) Investigators Chuengsamarn et al. of Thailand reported people with pre-diabetes who took 1500mg of a highly concentrated curcumin supplement (or is it a drug?) for nine months had a 16.4% reduction in diagnosable type 2 diabetes, when compared to the placebo group. More interestingly 0% of those taking curcumin transitioned to diabetes (said differently- no one taking curcumin developed diabetes)!In addition to reductions in fasting blood sugar, and hemoglobin A1c (a 3-month measure of average glucose), people taking curcumin appeared to have reduced need for insulin, demonstrated in their results as increased insulin sensitivity. The authors also reported an improvement in beta-cell function (i.e., the cells that produce insulin), yet this is likely a relative improvement, and not necessarily a change in the number or capacity of the cells. (In this trial, those receiving curcumin also had a reduction in c-peptide, a biomarker of longer-term insulin production; again suggesting an overall reduced need for insulin).
Study Quality Assessment & Scientific Curiosity
In my brief assessment, this trial is designed rather well, and was performed in a modestly-sized sample of participants (n=237) adding strength to the results; although the trial is limited in ethnic representation and therefore not necessarily generalizable to other ethnic groups. That said, the trial was very well described, with standardized interventions (including a standardized diet and lifestyle intervention before randomization) plus clearly defined outcome measures. The consistency of the findings also lends credibility, and points to a promising mechanism.
One curiosity is that most studies of oral curcumin administration in people have demonstrated its bioavailability to be very low (curcumin was undetectable in serum following oral doses up to 8g daily or in liver tissue following doses up to 3.6 grams daily). (2, 3) However, doses of 3.6 grams of mixed curcuminoids have increased serum concentrations in other studies (still only in the 10nmol/L range), and were well tolerated. (4) Based on the low dose administered in this trial, the findings support a potentially gut-based mechanism of action, i.e., one not requiring systemic bioavailability. Unfortunately the investigators did not report changes in blood or urine concentrations of the compounds administered, nor other biomarkers that may have provided insight into potential tissue sites of activity.
Implications
Although highly provocative, this study requires replication in other populations before this potential treatment goes "prime time". The trial, while well-designed, is still of short duration, i.e., nine months. However, given the long-term safety of these compounds (there were no adverse events in the curcumin group of this trial), the promising results of numerous studies suggesting health benefits, and the overwhelming historical use in the culinary traditions of many cultures, there is reason to eat turmeric! Even a lot of it!! As often as you'd like!If you have pre-diabetes, and decide to try turmeric as a supplement, or especially if you try a concentrated curcumin product, work with your naturopathic, or other primary care provider, to monitor your lab changes periodically. Remember, improvements in diet and increases in physical activity are the only time-tested, completely natural ways to prevent diabetes!
In health-
Ryan Bradley, ND, MPH and Erica Oberg, ND, MPH
P.S. For more reading on the potential mechanisms of herbs and spices to impact diabetes, see Complementary Corner on the website of the Diabetes Action Research and Education Foundation follow this link.
Citations:
1. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C,
Jirawatnotai S. Curcumin extract for prevention of type 2
diabetes. Diabetes
Care. 2012 Nov;35(11):2121-7. doi: 10.2337/dc12-0116. Epub
2012 Jul 6. PubMed
PMID: 22773702; PubMed Central PMCID: PMC3476912.
2. Lao CD, Ruffin MT 4th, Normolle D, Heath DD, Murray SI, Bailey JM, Boggs ME,
Crowell J, Rock CL, Brenner DE. Dose escalation of a curcuminoid formulation. BMC
Complement Altern Med. 2006 Mar 17;6:10. PubMed PMID: 16545122; PubMed Central
PMCID: PMC1434783.
3. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB,
Sharma RA, Steward WP,
Gescher AJ, Berry DP. Detection of curcumin and its
metabolites in hepatic tissue
and portal blood of patients following oral administration.
Br J Cancer. 2004 Mar
8;90(5):1011-5. PubMed PMID: 14997198; PubMed Central PMCID:
PMC2409622.
4. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A,
Hewitt HR, Marczylo TH,
Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ,
Steward WP. Phase I
clinical trial of oral curcumin: biomarkers of systemic
activity and compliance.
Clin Cancer Res. 2004 Oct 15;10(20):6847-54. PubMed PMID:
15501961.